Several other factors have been identified as potentially increasing the risk of IFD (all p < 0.05): lack of response to VEN + HMA therapy [46], non‐favourable European LeukemiaNet risk classification [48], presence of prolonged/chronic neutropenia [48, 51], poor patient physical fitness [47], presence of the TP53 mutation [47] and (in contrast to the FLT3 inhibitor study above [42]) younger age [47]. This evidence concerns the gene FLT3 and neutropenia.